Merck accelerator welcomes biotech start-ups specializing in AI and machine learning

By Rachel Arthur

- Last updated on GMT

Pic:getty/olemedia
Pic:getty/olemedia

Related tags start-ups Merck Artificial intelligence AI machine learning MSD

Merck (MSD outside the US and Canada) is welcoming applications from early-stage biomedical start-ups for its newly launched Merck Digital Sciences Studio (MDSS): which seeks to support technologies for drug discovery and development.

The 10-month accelerator program will support participating start-ups with direct investment, access to Azure Cloud computing and opportunities to pilot their technologies in collaboration with discovery and clinical scientists at Merck.

It is taking applications for 12 spots for the first MDSS cohort beginning in October, with the deadline for applications set as September 1.

'Tremendous opportunity' in AI

Digital technologies are already enabling innovation in biomarker and drug discovery and development in the areas of target identification, lead discovery, pre-clinical development, and clinical development. Through MDSS, Merck and its collaborators will selectively accelerate and pilot novel and innovative digital technologies that are strategically aligned with Merck’s life science research areas.

Startups developing artificial intelligence (AI) and machine learning (ML) applications will be prioritized, says Fiona Marshall, senior vice president, Discovery, Preclinical and Translational Medicine at Merck Research Laboratories.

“The biopharmaceutical industry has only just started to harness the tremendous opportunity presented by emerging technological developments in AI and ML.

“The MDSS will provide a collaborative and entrepreneurial setting where scientists have access to the tools and expertise to fuel important innovations that advance drug discovery and development.”

The MDSS is a collaboration between Merck and the New Jersey Innovation Institute (NJII), a New Jersey Institute of Technology corporation, with investments from the Merck Global Health Innovation Fund, Northpond Ventures and McKesson Ventures. Technology support will be provided by Microsoft for Startups.

The MDSS will have locations in Newark, NJ and Cambridge, MA.

Entrepreneurs can apply via the MDSS website​.

Related news

Related products

show more

How a Clinical MDR Helps with Data Quality

How a Clinical MDR Helps with Data Quality

Formedix | 16-Jan-2023 | Technical / White Paper

This article covers the many ways a clinical metadata repository helps with data quality in the clinical trial process, and how it ultimately helps to...

Optimizing Adherence in DCTs

Optimizing Adherence in DCTs

PPD - Decentralized Clinical Trials | 12-Jan-2023 | Technical / White Paper

Prioritizing greater patient-centricity and creating an opportunity to reach unprecedented patient groups, decentralized and hybrid clinical trials are...

PPD is Supporting Complex EU DCTs

PPD is Supporting Complex EU DCTs

PPD - Decentralized Clinical Trials | 05-Jan-2023 | Technical / White Paper

PPD supports European DCTs and clinical trial sponsors with a holistic and comprehensive approach

What should a clinical metadata repository do?

What should a clinical metadata repository do?

Formedix | 14-Dec-2022 | Technical / White Paper

Choosing a clinical metadata repository (MDR) software can be a tough task as the capabilities and features of your chosen MDR could make or break your...

Related suppliers

Follow us

Products

View more

Webinars